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72Early and Long-Term Responses to Anti–Vascular
Endothelial Growth Factor Therapy in Diabetic
Macular Edema: Analysis of Protocol I DataVICTOR H. GONZALEZ, JOANNA CAMPBELL, NANCY M. HOLEKAMP, SZILA´RD KISS, ANAT LOEWENSTEIN,
ALBERT J. AUGUSTIN, JULIA MA, ALLEN C. HO, VAISHALI PATEL, SCOTT M. WHITCUP, AND
PRAVIN U. DUGEL PURPOSE: To determine whether early visual acuity
response to ranibizumab in diabetic macular edema is
associated with long-term outcome.
 DESIGN: Post hoc analysis of randomized controlled
trial data.
 METHODS: Pooled data from the ranibizumab plus
prompt and deferred laser treatment arms of the Diabetic
Retinopathy Clinical Research Network’s Protocol I
study were used to explore the relationship between early
(week 12) and late (weeks 52–156) visual acuity
response (mean change from baseline in best-corrected
visual acuity [CFB BCVA]; categorized improvement
[<5, 5–9, or ‡10 Early Treatment Diabetic Retinopathy
Study (ETDRS) letters] in BCVA).
 RESULTS: In the analysis population (340 eyes),<5-,
5- to 9-, and ‡10-letter BCVA improvements occurred in
39.7%, 23.2%, and 37.1% of eyes, respectively, at
12 weeks, and 34.2%, 16.5%, and 49.3% of eyes at
156 weeks. Within each early BCVA response category
(<5, 5–9, and ‡10 letters of improvement at 12 weeks),
mean CFB BCVA at 52–156 weeks varied by<5 letters
from that at 12 weeks. CFB BCVA and <5-letter
improvement at 12 weeks showed significant positive
and negative association, respectively, with CFB BCVA
and ‡10-letter improvement at 52 and 156weeks. Similar
relationships were demonstrated in eyes with baseline
BCVA <69 letters, and associations remained signifi-
cant after multivariate adjustment for potential con-
founders.upplemental Material available at AJO.com.
r publication Sep 9, 2016.
Valley Retina Institute (V.H.G.), McAllen, Texas; Allergan
M., V.P.), Irvine, California; Pepose Vision Institute and
University School of Medicine (N.M.H.), St Louis,
eill Cornell Medical College (S.K.), New York, New York;
of Ophthalmology (A.L.), Tel Aviv Medical Center and
ulty of Medicine, Tel Aviv University, Tel Aviv, Israel;
of Ophthalmology (A.J.A.), Staedtisches Klinikum
Karlsruhe, Germany; Wills Eye Hospital (A.C.H.),
, Pennsylvania; Jules Stein Eye Institute (S.M.W.), David
ol of Medicine at UCLA, Los Angeles, California; Retinal
of Arizona (P.U.D.), Phoenix, Arizona; and Department of
ogy (P.U.D.), Keck School of Medicine, University of
lifornia, Los Angeles, California.
to Victor H. Gonzalez, Valley Retina Institute, 1309 East
ite 1, McAllen, TX 78503; e-mail: maculadoc@aol.com
© 2016 THE AUTHORS. PUB CONCLUSIONS: Ranibizumab ± laser therapy resulted
in similar rates (w40%) of suboptimal (<5-letter) and
pronounced (‡10-letter) BCVA improvement at
12 weeks. Eyes with suboptimal early BCVA response
showed poorer long-term visual outcomes than eyes
with pronounced early response (mean improvement
3.0 vs 13.8 letters at 156 weeks). (Am J Ophthalmol
2016;172:72–79.  2016 The Authors. Published by
Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).)
M
ULTIPLE RANDOMIZED CLINICAL TRIALS INDI-
cate that intravitreal anti–vascular endothelial
growth factor (VEGF) therapy, used alone or
in conjunction with focal/grid laser photocoagulation, is
more effective than laser photocoagulation alone in
improving visual acuity in diabetic macular edema
(DME), withw30%–70% of patients achieving >_10-letter
improvement and w10%–40% of patients achieving
>_15-letter improvement in best-corrected visual acuity
(BCVA) after 1 year of treatment.1–6 However, even
with the intensive treatment schedules (monthly or near-
monthly intravitreal injections for the first 12 months)
and close patient monitoring typically employed in
controlled clinical trials, more than 35% of patients with
DME fail to achieve >_10-letter improvement in BCVA
and more than 55% fail to achieve >_15-letter improvement
after 2 years of first-line anti-VEGF therapy.7–9 Although
anti-VEGF therapy is generally considered suitable first-
line therapy for center-involved DME, clearly not all
DME patients respond satisfactorily to anti-VEGF agents.
Early identification of those patients who are likely to
prove unresponsive or only partly responsive to long-term
anti-VEGF therapy would enable more timely consider-
ation of potential changes to their treatment regimens
that might prove more effective in improving visual func-
tion and/or preventing vision loss. To this end, the EARLY
(Early Anti-VEGF Response and Long-term efficacY) pro-
gram, a series of post hoc analyses of data from the Diabetic
Retinopathy Clinical Research Network’s (DRCR.net)
Protocol I study of ranibizumab plus laser in DME,3 was
initiated to explore the relationship between early and0002-9394
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long-term anatomic and visual acuity responses to anti-
VEGF therapy. The present analysis assesses the strength
of the association between visual acuity outcome after
12 weeks of anti-VEGF therapy (ie, after 3 monthly intra-
vitreal injections) and visual acuity outcomes at 1 and
3 years.METHODS
 STUDY OVERVIEW: In Protocol I (clinicaltrials.gov
identifier NCT00445003), a large, prospective, multi-
center trial in DME patients with baseline BCVA of
78-24 Early Treatment Diabetic Retinopathy Study
(ETDRS) letters (approximate Snellen equivalent 20/32
to 20/320) and optical coherence tomography (OCT)-
determined central subfield retinal thickness (CRT)
>_250 mm, study eyes were randomized to 1 of 4 treatment
arms: (1) sham injection plus prompt (within 7–10 days)
focal/grid photocoagulation, (2) intravitreal ranibizumab
0.5 mg plus prompt (within 7–10 days) focal/grid photoco-
agulation, (3) intravitreal ranibizumab 0.5 mg plus deferred
(after >_24 weeks) focal/grid photocoagulation, or (4) intra-
vitreal triamcinolone 4 mg plus prompt (within 7–10 days)
focal/grid photocoagulation.3 Intravitreal ranibizumab and
sham injections were performed every 4 weeks for the first
12 weeks of the study and as needed thereafter; laser
retreatment was determined by the extent of central mac-
ular edema. Eyes that met prespecified ‘‘failure’’ or ‘‘futility’’
criteria or were withdrawn from study treatment at the in-
vestigator’s discretion could be switched to an alternative
treatment. Follow-up examinations, including measure-
ments of BCVA and OCT-derived CRT, were performed
every 4 weeks for the first year and every 4–16 weeks during
the second and third years of the study. Follow-up was
planned for 3 years, with the primary outcome being at
1 year. After review of study findings at 2 years, which
demonstrated an efficacy advantage in the ranibizumab
treatment arms,7 patients in the sham injection and intra-
vitreal triamcinolone treatment arms were offered the
option of switching to ranibizumab treatment for the third
year.10 The study follow-up period was subsequently
extended to 5 years.11
 VISUAL ACUITY RESPONSE ANALYSES: The present
analysis is based on 3-year study data from those patients
in Protocol I who were randomized to treatment with
ranibizumab plus either prompt or deferred laser, and
who provided an observed BCVA reading at 12 weeks.
To evaluate the strength of the association between early
treatment response and long-term outcome, study eyes
were separately categorized according to the change
from baseline in BCVA (<5-letter, 5- to 9-letter, or
>_10-letter improvement) at 12 weeks. Visual acuity out-
comes at subsequent follow-up visits were determinedVOL. 172 EARLY AND LATE ANTI-VEGF RESPONwithin study cohorts based on these initial BCVA
response categories. Missing data owing to missed visits
after week 12 were imputed using the last-observation-
carried-forward method. BCVA readings obtained after
introduction of alternative treatments to the randomly
assigned study treatment were included in the analysis.
In view of the possibility that the improvement in
BCVA might be truncated by a ceiling effect among
eyes initiating treatment with good visual acuity, a sensi-
tivity analysis was performed in the subset of eyes with
baseline BCVA <69 ETDRS letters (Snellen equivalent
w20/50). Additional sensitivity analyses were performed
in study eyes randomized to treatment with intravitreal
ranibizumab plus deferred laser and in eyes categorized
according to early BCVA response at other time points,
ranging from 4 to 24 weeks after treatment initiation.
 STATISTICAL METHODS: Intercohort comparisons of
baseline characteristics were performed using the Student
t test for continuous variables and Pearson x2 test for cate-
gorical variables. Intercohort comparisons of vision out-
comes (change from baseline in BCVA) were performed
using analysis of variance. Multiple linear and logistic
regression analysis was performed to assess the relationship
between early (12-week) and late (52- and 156-week)
visual acuity outcomes after controlling for multiple poten-
tial confounding factors. Additional covariates of interest
included age, sex, baseline BCVA and CRT, proportional
CRT response (>_20% vs <20% reduction from baseline)
at 12 weeks, cumulative number of ranibizumab injections
and laser treatments received at 52 and 156 weeks, and
prior receipt of DME treatment. P values were determined
using Student t test (linear regression) and Wald’s x2 test
(logistic regression). Statistical analyses were performed
with SAS versions 9.3 and 9.4 (SAS Inc, Cary, North
Carolina, USA). A P value of <_.05 was considered statisti-
cally significant.RESULTS
IN TOTAL, 375 STUDY EYES WERE ASSIGNED TO THE
ranibizumab plus prompt laser and ranibizumab plus
deferred laser treatment arms in the Protocol I study. Of
these, 340 study eyes provided observed visual acuity
data and 335 study eyes provided observed OCT-derived
CRT data at 12 (6 2) weeks (pooled analysis population).
Within this overall population, sensitivity analyses were
conducted on 212 eyes that had baseline BCVA <69
ETDRS letters.
 VISUAL ACUITY OUTCOMES: Overall best-corrected visual
acuity response rate over time. Among the pooled analysis
population (n ¼ 340), 135 eyes (39.7%) showed <5-letter
improvement in BCVA at 12 weeks, 79 eyes (23.2%)73SE IN DIABETIC MACULAR EDEMA
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FIGURE 1. Mean (95% confidence interval) change from baseline (BL) in best-corrected visual acuity (BCVA) over time, catego-
rized by BCVA response at 12 weeks, in pooled study eyes treated with ranibizumabD prompt/deferred laser (n[ 340 eyes).P value
for comparison across all 3 BCVA categories (for each visit) is based on analysis of variance.showed 5- to 9-letter improvement, and 126 eyes (37.1%)
showed >_10-letter improvement; within this latter
category, 60 eyes (17.6% of total) achieved >_15-letter
improvement. Overall, at study end (156 weeks), 116
eyes (34.2%) showed <5-letter improvement, 56 eyes
(16.5%) showed 5- to 9-letter improvement, and 167
eyes (49.3%) showed >_10-letter improvement from
baseline; of this latter group, 98 eyes (28.9% of total)
achieved >_15-letter improvement.
Relationship between best-corrected visual acuity responses at
12 weeks and 1 and 3 years. Within each of the initial
BCVA response categories (ie, BCVA improvement <5
letters, 5–9 letters, and >_10 letters at 12 weeks), the
mean BCVA response (BCVA change from baseline) of
study eyes at 52 weeks onward did not vary by more
than 5 ETDRS letters from the observed mean BCVA
response at 12 weeks (Figure 1). Across the 3 response
categories, intercohort differences in mean BCVA
response (BCVA change from baseline) were statistically
significant (P < .001) at each 4-week time point.
Marked intersubject variation in BCVA response was
evident within each initial response category, and a
limited initial BCVA response (<5-letter improvement
[deterioration, no change, or 1- to 4-letter improvement]
at 12 weeks) did not entirely preclude later development
of a pronounced BCVA response during long-term
treatment. However, development of the response was
slow.
Within the subset of eyes with <5-letter BCVA
improvement at 12 weeks, a minority of eyes achieved a
BCVA gain of >_10 ETDRS letters over the course of the
study: 23.0% at 52 weeks, rising marginally to 28.9% at
156 weeks (Figure 2). A smaller minority of eyes achieved
a BCVA gain of >_15 ETDRS letters: 6.7% at 52 weeks,74 AMERICAN JOURNAL OFincreasing to 14.8% at 156 weeks. Approximately one-
half of eyes continued to show <5-letter BCVA improve-
ment at these time points. Within the subset of eyes with a
pronounced initial BCVA response (>_10-letter improve-
ment at 12 weeks), most eyes maintained this response
over the course of the study: 81.7% at 52 weeks and
72.0% at 156 weeks, and approximately one-half of eyes
showed >_15-letter improvement at these time points
(61.1% and 47.2% of eyes, respectively) (Figure 3). A
small proportion of eyes with >_10-letter BCVA improve-
ment at 12 weeks experienced subsequent attenuation of
response to <5-letter improvement at 52 and 156 weeks.
Intercohort comparisons revealed significant differences
in the baseline characteristics of study eyes: eyes with
<5-letter improvement in BCVA at 12 weeks were older
and had a higher baseline BCVA and a lower baseline
CRT than eyes with >_10-letter improvement in BCVA
at 12 weeks (Table 1). In multiple logistic regression
analyses there was a negative, statistically significant asso-
ciation between limited BCVA response (<5-letter
improvement in BCVA from baseline) at 12 weeks and
pronounced BCVA response (>_10-letter improvement in
BCVA from baseline) at 52 weeks (odds ratio [OR] 0.20,
95% confidence interval [CI] 0.12–0.36; P < .001) and
156 weeks (OR 0.31, 95% CI 0.19–0.53; P < .001) after
adjusting for multiple patient characteristics, including
age, sex, prior DME treatment, baseline BCVA and
CRT, proportional CRT change (>_20% reduction) at
12 weeks, and cumulative number of ranibizumab injec-
tions and laser treatments administered. Of these, age
and baseline BCVA were also significantly associated
with a pronounced BCVA response (>_10-letter improve-
ment from baseline) at 52 weeks, and baseline BCVA
remained significantly associated with BCVA response at
study end (Table 2). Additionally, in multiple linearDECEMBER 2016OPHTHALMOLOGY
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FIGURE 2. Long-term best-corrected visual acuity (BCVA) outcomes in the subgroup of ranibizumab D prompt/deferred
laser–treated eyes with <5-letter improvement in BCVA at 12 weeks: frequency distribution of BCVA improvement
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(n [ 126 eyes).regression analyses BCVA response (BCVA change from
baseline) at 12 weeks showed a significant association
with BCVA response (BCVA change from baseline) at
52 weeks (coefficient estimate 0.72, standard error [SE]
0.07; P < .001) and 156 weeks (coefficient estimate
0.56, SE 0.10; P < .001) after adjusting for the standard
covariates listed above. Age and baseline BCVA also
showed significant associations with BCVA response
(change from baseline) at 52 weeks, although only base-
line BCVA remained significantly associated with
BCVA response at study end (Table 3).VOL. 172 EARLY AND LATE ANTI-VEGF RESPON SENSITIVITY ANALYSES: Eyes with baseline best-corrected
visual acuity <69 ETDRS letters. Among the subset of
eyes with baseline BCVA <69 ETDRS letters (n ¼ 212),
the distribution of early BCVA responses was marginally
more favorable than in the overall study population, with
<5-, 5- to 9-, and >_10-letter BCVA improvements
occurring in 32.1%, 21.2%, and 46.7% of eyes,
respectively, at 12 weeks. Of the eyes with baseline
BCVA <69 ETDRS letters and <5-letter improvement
at 12 weeks, a minority of eyes achieved a BCVA gain of
>_10 letters over the course of the study (35.3% at both75SE IN DIABETIC MACULAR EDEMA
TABLE 1. Baseline Characteristics of Pooled Study Eyes Treated With Ranibizumab þ Prompt/Deferred Laser, Categorized by
Best-Corrected Visual Acuity Response at 12 Weeks (N ¼ 340)
Parameter
BCVA Change From Baseline at 12 Weeks
P Valuea
<5-Letter Improvement
N ¼ 135
5- to 9-Letter Improvement
N ¼ 79
>_10-Letter Improvement
N ¼ 126
Age, mean 6 SD (y) 64.3 6 9.3 61.9 6 9.9 61.7 6 10.1 .036
Male sex, n (%) 78 (57.8) 38 (48.1) 75 (59.5) .775
Baseline BCVA, mean 6 SD (letters) 65.2 6 12.2 64.9 6 9.8 58.8 6 11.4 <.001
Baseline CRT, mean 6 SD (mm) 379 6 112 384 6 107 438 6 136 <.001
Prior DME treatment, n (%) 86 (63.7) 49 (62.0) 74 (58.7) .410
BCVA ¼ best-corrected visual acuity; CRT ¼ central retinal thickness; DME ¼ diabetic macular edema.
aComparison between <5-letter improvement and >_10-letter improvement categories, based on Student t test for continuous variables and
Pearson x2 test or Fisher exact test for categorical variables.
TABLE 3. Multiple Linear Regression Analysis of Change
From Baseline in Best-Corrected Visual Acuity at 52 and
156 Weeks: Pooled Study Eyes Treated With
Ranibizumab þ Prompt/Deferred Laser (N ¼ 335)
Parameter
Multiple Linear Regression of BCVA
Response at 52 and 156 Weeks
52 Weeks
N ¼ 335
156 Weeks
N ¼ 335
Estimate P Valuea Estimate P Valuea
Age 0.13 .016 0.10 .162
Sex 0.01 .991 0.66 .644
Baseline BCVA 0.22 <.001 0.25 <.001
Baseline CRT 0.01 .061 0.00 .946
BCVA CFB at week 12 0.72 <.001 0.56 <.001
>_20% CRT improvement
at week 12
1.59 .205 1.88 .268
Cumulative no. RAN
injections at week 52
or 156
0.09 .658 0.04 .721
Cumulative no. laser
treatments at week 52
or 156
0.66 .116 0.16 .684
Prior DME treatment 2.02 .054 0.16 .914
BCVA ¼ best-corrected visual acuity; CFB ¼ change from
baseline; CRT ¼ central retinal thickness; DME ¼ diabetic
macular edema; RAN ¼ ranibizumab.
aP value based on Student t test.
TABLE 2.Multiple Logistic Regression Analysis of >_10-Letter
Improvement in Best-Corrected Visual Acuity at 52 and
156 Weeks: Pooled Study Eyes Treated With
Ranibizumab þ Prompt/Deferred Laser (N ¼ 335)
Parameter
Multiple Logistic Regression of >_10-Letter
Improvement in BCVA at 52 and 156 Weeks
52 Weeks
N ¼ 335
156 Weeks
N ¼ 335
Odds
Ratio
P
Valuea
Odds
Ratio
P
Valuea
Age 0.96 .007 0.99 .407
Sex (F/M) 1.08 .768 0.89 .659
Baseline BCVA 0.93 <.001 0.94 <.001
Baseline CRT 1.00 .202 1.00 .779
BCVA CFB <5 letters
at week 12
0.20 <.001 0.31 <.001
>_20% CRT improvement
at week 12
1.80 .074 1.50 .174
Cumulative no. RAN
injections at week 52
or 156
0.94 .256 1.00 .919
Cumulative no. laser
treatments at week 52
or 156
0.85 .167 0.92 .269
Prior DME treatment 0.64 .113 0.85 .539
BCVA ¼ best-corrected visual acuity; CFB ¼ change from
baseline; CRT ¼ central retinal thickness; DME ¼ diabetic
macular edema; RAN ¼ ranibizumab.
aP value based on Wald x2 test for odds ratio ¼ 1.52 and 156 weeks). Multiple logistic and linear regression
findings in the subset of eyes with baseline BCVA <69
ETDRS letters were generally consistent with those in
the overall analysis population. There was a negative,
statistically significant association between limited
BCVA response (<5-letter improvement in BCVA from
baseline) at 12 weeks and pronounced BCVA response76 AMERICAN JOURNAL OF(>_10-letter improvement) at 52 weeks (OR 0.23, 95% CI
0.11–0.47; P < .001) and 156 weeks (OR 0.24, 95% CI
0.12–0.48; P < .001), after adjusting for the standard
covariates used in the main analysis. Likewise, BCVA
response (change in BCVA from baseline) at 12 weeks
was strongly associated with BCVA response at 52 weeks
(coefficient estimate 0.77, SE 0.09; P < .001) and
156 weeks (coefficient estimate 0.63, SE 0.13; P < .001),
after adjusting for the standard covariates.DECEMBER 2016OPHTHALMOLOGY
Other sensitivity analyses. As in the pooled analysis
population, multiple logistic and linear regression analyses
in the subset of eyes randomized to treatment with ranibi-
zumab plus deferred laser demonstrated significant associa-
tions between early and late BCVA outcomes. In separate
multiple linear regression analysis models, early BCVA
response (BCVA change from baseline) at each of the
examined time points (4, 8, 12, 16, and 24 weeks) was
found to show a significant association with long-term
BCVA response (BCVA change from baseline at 52, 104,
and 156 weeks), after controlling for the standard
covariates listed above (P < .001 for early BCVA
response parameter in all models).DISCUSSION
EVIDENCE FROM RANDOMIZED CLINICAL TRIALS OF
anti-VEGF therapy in DME suggests that the improvement
in visual acuity largely develops within the first 3–6 months
of treatment, with further, more modest gains occurring
over the longer term.3,8,9 In contrast, the anatomic
response appears to develop more gradually, and the
reduction in CRT may not level off until later in the
course of treatment.2,12
Our post hoc analysis of data from the DRCR.net Proto-
col I study indicates, firstly, that visual acuity outcomes
vary considerably in DME patients receiving ranibizumab
plus prompt or deferred laser treatment. After 3 months
of treatment,w40% of eyes show substantial improvement
in BCVA (>_10 letters), whereas a similar proportion show
at best only limited BCVA gain (<5 letters). Long-term
treatment produces only modest additional improvement
in these figures, with w50% of eyes achieving >_10-letter
gain and one third of eyes <5-letter gain after 3 years.
Secondly, the functional responses to ranibizumab that
are evident 12 weeks after treatment initiation are consis-
tently and robustly associated with subsequent responses
over the entire 3-year duration of treatment. Because base-
line BCVA is also an important determinant of treatment
response (the greatest letter gains occur in eyes with worse
baseline vision), it is possible that the association between
early and late BCVA response might be attributable to a
ceiling effect—namely, the limited scope for further letter
gain in the w40% of study eyes with relatively well-
preserved baseline vision (BCVA >_69 ETDRS letters;
Snellen equivalent w20/50). This appears unlikely, how-
ever, as an equally strong association was evident in the
subset of eyes with moderate vision loss (baseline BCVA
<69 ETDRS letters); these eyes, in contrast, are under
no such constraints in their ability to achieve large
(>_15-letter) gains in visual acuity. In keeping with findings
in the overall study eye population, early BCVA response
also proved to be significantly associated with long-term
visual acuity outcome in the subset of eyes treated withVOL. 172 EARLY AND LATE ANTI-VEGF RESPONranibizumab plus deferred laser. This latter scenario may
more closely mirror clinical practice, where the tendency
is to use laser as rescue therapy following intravitreal
ranibizumab monotherapy, rather than as adjunctive
therapy.13
It should be noted that a limited initial BCVA response
does not entirely preclude the possibility of future develop-
ment of a more complete BCVA response if treatment is
continued. Approximately 30% of the eyes that showed
<5-letter improvement in BCVA at 12 weeks (ie,w12%
of all study eyes) subsequently achieved a BCVA gain of
>_10 letters after 3 years of treatment, whereas w50%
continued with <5-letter improvement. The reason for
this delayed improvement in visual acuity in some eyes
but not in others is unclear: possible contributory factors
might include differences in diabetic retinopathy severity,
baseline BCVA, laser use, and intensity of pro re nata rani-
bizumab treatment and VEGF suppression during follow-
up.14,15 In the absence of comparative data on the
clinical characteristics and treatment patterns of patients
in the different response categories, this analysis provides
no prognostic clues that would assist in identifying likely
long-term treatment responders among patients who
show a limited early BCVA response to ranibizumab.
Given these constraints, and the relatively low probability
of further visual acuity improvement after a suboptimal
initial response to ranibizumab with prompt or deferred
laser therapy, it may be appropriate to consider adjustments
to the treatment regimen for patients in this category.
Potentially these might include use of adjunctive agents
acting through non-VEGF–mediated pathways or replace-
ment of ranibizumab—either with another anti-VEGF
agent, laser, or a sustained-release corticosteroid. Little is
currently known, however, about the effectiveness of
non-VEGF–mediated treatments in eyes with limited
response to previous anti-VEGF therapy. Neither the Pro-
tocol I study nor the current analysis addresses the question
of whether patients with suboptimal response to ranibizu-
mab with prompt or deferred laser treatment are likely to
achieve better visual acuity outcomes with alternative
therapies, or whether any specific treatment pathway offers
a potential efficacy advantage. The subsequent treatment
algorithm for patients with limited visual response to initial
anti-VEGF therapy is, therefore, uncertain. The clinical
importance of this topic has been recognized and is the sub-
ject of ongoing prospective clinical trials.
Consistent with findings from earlier investigations of
factors influencing the visual acuity response to anti-
VEGF therapy in DME,14,15 we found that OCT-defined
anatomic response (>_20% CRT reduction) at 12 weeks
showed an inconsistent and generally weak association
with long-term visual acuity outcome. The absence of a
consistent association between early anatomic and late
visual outcomes is not unexpected, because retinal edema
represents only 1 of several possible causes of reduced visual
acuity.77SE IN DIABETIC MACULAR EDEMA
It should be borne in mind that our findings are based
on data generated from a rigorously conducted clinical
trial in which patients were evaluated consistently every
4 weeks during the first year of treatment, with possible
extension of visit intervals to every 8 or 16 weeks during
the second and third years if predetermined treatment
success criteria (BCVA Snellen equivalent 20/20 or
better or OCT-derived CRT <_250 mm) were satisfied.10
In clinical practice, DME patients typically make frequent
outpatient visits, with most of these being for nonop-
hthalmologic reasons,16 making it difficult to maintain
intensive anti-VEGF treatment and monitoring over the
long term. In a retrospective study of US claims data
from the IMS LifeLink health plan database (Danbury,
CT; 2010–2011 data), patients with newly diagnosed
DME made on average 5.3 ophthalmologist visits during
the first 12 months of anti-VEGF therapy (compared
with an average of 12 visits in the Protocol I study) and
received an average of 3.6 intravitreal injections per eye
over this period (compared with a median of 9 injections
per eye in the Protocol I study), and fewer than 6% of
patients received 10 or more injections over the first
12 months.17 Our findings therefore represent a best-
case scenario for DME patients. In real-world settings
with lower rates of anti-VEGF injection, rates of subopti-
mal visual acuity response may be even greater.18,19
Genotypic and phenotypic factors may contribute to the
suboptimal response to anti-VEGF therapy. Inter-
individual variation in responsiveness to anti-VEGF ther-
apy in DME may be attributable in part to polymorphism
in the VEGF gene, and/or to differences in VEGF gene
expression.20,21 The response to anti-VEGF therapy may
be limited as a result of enhanced VEGF expression and/
or redundancy of the VEGF target, thereby necessitating
a more intensive dosing regimen or use of adjunctive treat-
ments with alternative modes of action.20 Metabolic fac-
tors such as glucose regulation also appear to affect the
visual and anatomic response to anti-VEGF therapy in
eyes with DME, with tight glycemic control throughout
the duration of anti-VEGF treatment leading to more
robust improvements in BCVA and CRT.22 However,
available evidence suggests that baseline biochemical
indices such as serum hemoglobinA1c level show little cor-
relation with subsequent response to anti-VEGF therapy.2278 AMERICAN JOURNAL OFLimitations of this analysis include its post hoc nature.
Additional factors that might potentially affect the success
or failure of anti-VEGF therapy in DME, such as duration
of DME, were not reported in the Protocol I study; there-
fore, these data were unavailable for inclusion in the anal-
ysis. Potential associations with other aspects of DME
status (eg, presence of ischemia, severity of diabetic reti-
nopathy), and level of glycemic control remain of interest
for future analysis. Additionally, although this analysis
assesses vision improvement, it does not determine
whether the improvement results in attainment of near-
normal levels of visual acuity or leaves patients with signif-
icant residual visual impairment. Likewise, the analysis
does not establish the optimal time point for measuring
early BCVA response. It should be noted, however, that
in the linear regression models exploring the relationship
between long-term BCVA response and BCVA/CRT
response during the first 4–24 weeks of treatment, the
regression coefficients associated with BCVA response at
16 weeks and 24 weeks were no greater than those associ-
ated with BCVA response at 12 weeks, which incidentally
coincides with the end of the treatment initiation phase
(receipt of the 3 initial monthly intraocular anti-VEGF
injections) in clinical practice. These limitations notwith-
standing, this study is the first to demonstrate the signifi-
cance of early treatment response as a factor associated
with long-term visual acuity outcome with anti-VEGF
therapy in DME.
In conclusion, this analysis indicates that for those eyes
that show limited initial visual improvement with anti-
VEGF therapy, only a minority (w20%–30%) can be
expected to develop a clinically significant visual response
with continued intensive anti-VEGF treatment and moni-
toring over the following 1–3 years. Outside the random-
ized clinical trial setting, maintenance of the intensive
treatment schedule and monitoring required to achieve
these visual acuity gains presents a considerable challenge.
Accordingly, for patients with a suboptimal visual response
after the first 3 intravitreal anti-VEGF injections it may be
appropriate to consider adjustments to the treatment
regimen. Specific recommendations for subsequent medical
management of patients with limited initial response to
anti-VEGF therapy must, however, await the results of
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